Synlogic’s (SYBX) Buy Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Synlogic (NASDAQ:SYBX) in a research note issued to investors on Monday morning, AnalystRatings.com reports. They currently have a $13.00 price objective on the biotechnology company’s stock.

A number of other analysts have also issued reports on SYBX. Zacks Investment Research upgraded Synlogic from a hold rating to a buy rating and set a $2.75 price target for the company in a report on Thursday, January 9th. Chardan Capital reiterated a buy rating on shares of Synlogic in a report on Thursday, September 19th. ValuEngine upgraded Synlogic from a hold rating to a buy rating in a report on Friday, January 3rd. Finally, Piper Jaffray Companies reiterated an overweight rating and issued a $7.00 price target (down previously from $10.00) on shares of Synlogic in a report on Wednesday, November 13th. One research analyst has rated the stock with a sell rating, one has given a hold rating and eight have given a buy rating to the company’s stock. Synlogic presently has a consensus rating of Buy and an average target price of $13.72.

Shares of NASDAQ:SYBX opened at $3.15 on Monday. Synlogic has a 1 year low of $1.91 and a 1 year high of $11.43. The business has a 50 day simple moving average of $2.43 and a two-hundred day simple moving average of $3.56. The firm has a market capitalization of $88.15 million, a PE ratio of -1.55 and a beta of 2.61. The company has a debt-to-equity ratio of 0.14, a current ratio of 12.70 and a quick ratio of 12.70.

Synlogic (NASDAQ:SYBX) last announced its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported ($0.39) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.48) by $0.09. The firm had revenue of $0.31 million during the quarter, compared to analyst estimates of $0.46 million. Synlogic had a negative return on equity of 34.49% and a negative net margin of 4,574.82%. Equities research analysts expect that Synlogic will post -1.8 EPS for the current fiscal year.

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Charles Schwab Investment Management Inc. lifted its holdings in Synlogic by 11.1% during the second quarter. Charles Schwab Investment Management Inc. now owns 37,208 shares of the biotechnology company’s stock worth $339,000 after buying an additional 3,708 shares during the period. Northern Trust Corp lifted its holdings in Synlogic by 17.1% during the second quarter. Northern Trust Corp now owns 201,613 shares of the biotechnology company’s stock worth $1,835,000 after buying an additional 29,401 shares during the period. Parametric Portfolio Associates LLC purchased a new stake in Synlogic during the second quarter worth $195,000. BlackRock Inc. lifted its holdings in Synlogic by 9.4% during the second quarter. BlackRock Inc. now owns 1,317,063 shares of the biotechnology company’s stock worth $11,986,000 after buying an additional 113,665 shares during the period. Finally, Vanguard Group Inc. lifted its holdings in Synlogic by 0.3% during the second quarter. Vanguard Group Inc. now owns 770,641 shares of the biotechnology company’s stock worth $7,013,000 after buying an additional 2,558 shares during the period. Hedge funds and other institutional investors own 61.00% of the company’s stock.

About Synlogic

Synlogic, Inc a clinical-stage biopharmaceutical company, focuses on the discovery and development of synthetic biotic medicines to treat metabolic, inflammatory, and cancer diseases in the United States. Its lead therapeutic programs include SYNB1020, an oral therapy for the treatment of hyperammonemia, which includes patients with liver diseases, such as hepatic encephalopathy, as well as patients with urea cycle disorders; and SYNB1618, an oral therapy that is in Phase I/IIa clinical trial to treat phenylketonuria.

Recommended Story: Stock Symbol

Analyst Recommendations for Synlogic (NASDAQ:SYBX)

Receive News & Ratings for Synlogic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synlogic and related companies with MarketBeat.com's FREE daily email newsletter.